Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

21 equities research analysts have issued 1 year target prices for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $405.00. On average, they predict the company's share price to reach $247.40 in the next twelve months. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. Since then, ALNY shares have decreased by 26.1% and is now trading at $175.52.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ALNY earnings forecast.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.21) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by $0.49. The biopharmaceutical company had revenue of $318.75 million for the quarter, compared to analyst estimates of $331.73 million. Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative trailing twelve-month return on equity of 1,287.80%.

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED).

Alnylam Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.44 billion.

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital World Investors (13.20%), Baillie Gifford & Co. (6.74%), BlackRock Inc. (6.71%), State Street Corp (2.31%), Capital International Investors (2.30%) and Capital Research Global Investors (1.88%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $175.52.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $21.94 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.61) on an earnings per share basis.

The company employs 2,002 workers across the globe.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.